CN101918377A - 新颖化合物和组合物以及使用方法 - Google Patents

新颖化合物和组合物以及使用方法 Download PDF

Info

Publication number
CN101918377A
CN101918377A CN2008801234080A CN200880123408A CN101918377A CN 101918377 A CN101918377 A CN 101918377A CN 2008801234080 A CN2008801234080 A CN 2008801234080A CN 200880123408 A CN200880123408 A CN 200880123408A CN 101918377 A CN101918377 A CN 101918377A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
substituted
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801234080A
Other languages
English (en)
Chinese (zh)
Inventor
巴里·D·夸尔特
让-吕克·吉拉尔代
埃斯米尔·古尼奇
利-泰恩·叶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101918377(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Priority to CN201210376284.5A priority Critical patent/CN103058944B/zh
Publication of CN101918377A publication Critical patent/CN101918377A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2008801234080A 2007-11-27 2008-11-26 新颖化合物和组合物以及使用方法 Pending CN101918377A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210376284.5A CN103058944B (zh) 2007-11-27 2008-11-26 调节血液尿酸水平的化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99057407P 2007-11-27 2007-11-27
US60/990,574 2007-11-27
US9438808P 2008-09-04 2008-09-04
US61/094,388 2008-09-04
PCT/US2008/084988 WO2009070740A2 (en) 2007-11-27 2008-11-26 Novel compounds and compositions and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201210376284.5A Division CN103058944B (zh) 2007-11-27 2008-11-26 调节血液尿酸水平的化合物
CN201210122406.8A Division CN102643241B (zh) 2007-11-27 2008-11-26 化合物和组合物以及使用方法

Publications (1)

Publication Number Publication Date
CN101918377A true CN101918377A (zh) 2010-12-15

Family

ID=40679222

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2008801234080A Pending CN101918377A (zh) 2007-11-27 2008-11-26 新颖化合物和组合物以及使用方法
CN201210376284.5A Active CN103058944B (zh) 2007-11-27 2008-11-26 调节血液尿酸水平的化合物
CN201210122406.8A Active CN102643241B (zh) 2007-11-27 2008-11-26 化合物和组合物以及使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201210376284.5A Active CN103058944B (zh) 2007-11-27 2008-11-26 调节血液尿酸水平的化合物
CN201210122406.8A Active CN102643241B (zh) 2007-11-27 2008-11-26 化合物和组合物以及使用方法

Country Status (35)

Country Link
US (8) US8084483B2 (enExample)
EP (2) EP2217577B1 (enExample)
JP (3) JP5099794B2 (enExample)
KR (2) KR101411806B1 (enExample)
CN (3) CN101918377A (enExample)
AR (1) AR069753A1 (enExample)
AU (2) AU2008329673C1 (enExample)
BR (1) BRPI0819847B1 (enExample)
CA (1) CA2706858C (enExample)
CL (1) CL2008003529A1 (enExample)
CY (1) CY2019010I1 (enExample)
DK (1) DK2217577T3 (enExample)
EA (2) EA201270666A1 (enExample)
EC (1) ECSP10010310A (enExample)
ES (1) ES2513390T3 (enExample)
HR (1) HRP20140950T1 (enExample)
HU (1) HUS1900009I1 (enExample)
IL (1) IL205974A (enExample)
LT (1) LTPA2019003I1 (enExample)
LU (1) LUC00103I2 (enExample)
MA (1) MA31936B1 (enExample)
ME (2) ME01996B (enExample)
MX (1) MX2010005776A (enExample)
MY (1) MY147370A (enExample)
NO (1) NO2016016I2 (enExample)
NZ (4) NZ601774A (enExample)
PL (1) PL2217577T3 (enExample)
PT (1) PT2217577E (enExample)
RS (1) RS53569B1 (enExample)
SG (1) SG183721A1 (enExample)
SI (1) SI2217577T1 (enExample)
TN (1) TN2010000237A1 (enExample)
TW (1) TWI415840B (enExample)
WO (1) WO2009070740A2 (enExample)
ZA (1) ZA201003769B (enExample)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973530A (zh) * 2012-12-14 2013-03-20 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
CN103524440A (zh) * 2013-10-15 2014-01-22 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103702986A (zh) * 2011-05-24 2014-04-02 阿迪亚生命科学公司 高血压和高尿酸血症
CN104066323A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 用于治疗患者亚群中痛风的方法
CN104066430A (zh) * 2012-01-27 2014-09-24 帝人制药株式会社 糖尿病的治疗药
CN104066324A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 治疗痛风急性发作的方法
CN104068288A (zh) * 2014-07-25 2014-10-01 许伟琦 一种防尿路结石的饲料添加剂
CN104326998A (zh) * 2014-10-27 2015-02-04 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104327000A (zh) * 2014-10-27 2015-02-04 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326993A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341363A (zh) * 2014-10-27 2015-02-11 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341362A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370842A (zh) * 2014-10-27 2015-02-25 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370841A (zh) * 2014-10-27 2015-02-25 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104447590A (zh) * 2013-11-22 2015-03-25 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的晶型及其制备方法
CN104478815A (zh) * 2013-12-23 2015-04-01 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的多种盐、它们的晶型及其制备方法
CN104529919A (zh) * 2013-12-20 2015-04-22 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的共晶及其制备方法
CN104736522A (zh) * 2012-07-03 2015-06-24 阿迪亚生命科学公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的制备
CN104797570A (zh) * 2012-11-14 2015-07-22 帝人制药株式会社 吡啶衍生物
CN105263913A (zh) * 2013-06-14 2016-01-20 广东东阳光药业有限公司 硫代1,2,4-三唑衍生物及其制备方法
CN105985295A (zh) * 2015-02-17 2016-10-05 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
WO2016155653A1 (zh) * 2015-04-03 2016-10-06 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN107108478A (zh) * 2014-12-29 2017-08-29 日本化学药品株式会社 Urat1抑制剂
CN107337649A (zh) * 2016-04-29 2017-11-10 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
WO2017215589A1 (zh) * 2016-06-17 2017-12-21 南京明德新药研发股份有限公司 一种卤代化合物及其轴手性异构体
WO2018023851A1 (zh) * 2016-08-03 2018-02-08 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
CN107921054A (zh) * 2015-08-26 2018-04-17 斯塔根有限公司 细胞内atp增强剂
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
CN108164471A (zh) * 2016-12-07 2018-06-15 浙江京新药业股份有限公司 Lesinurad衍生物及其制备方法和用途
WO2018210354A1 (zh) * 2017-05-17 2018-11-22 浙江华海药业股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2019114838A1 (zh) * 2017-12-15 2019-06-20 南京明德新药研发股份有限公司 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
CN111320588A (zh) * 2018-12-14 2020-06-23 上海奥博生物医药技术有限公司 一种纯化Lesinurad杂质的方法

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101241716B1 (ko) 2004-08-25 2013-03-08 아디아 바이오사이언스즈 인크. ＨＩＶ 역 전사 효소의 억제제로서 Ｓ-트리아졸릴 α-메르캅토아세트아닐리드
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
DK2217577T3 (da) 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2328874A4 (en) * 2008-09-04 2012-05-09 Ardea Biosciences Inc COMPOSITES, COMPOSITIONS AND METHOD FOR THEIR USE FOR MODULING THE HARNIC ACID MIRROR
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
US20110244049A1 (en) * 2008-10-24 2011-10-06 Ardea Biosciences Inc. Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof, and methods for preparing and using same
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
JP2012527475A (ja) * 2009-05-20 2012-11-08 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及び方法
US8372807B2 (en) 2009-05-20 2013-02-12 Ardea Biosciences, Inc. Methods of modulating uric acid levels
SG182404A1 (en) * 2010-01-08 2012-08-30 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
EP3659601A1 (en) * 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
HUE038265T2 (hu) 2010-06-15 2018-10-29 Ardea Biosciences Inc Köszvény és hiperurikémia kezelése
CA2802692C (en) * 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetate compounds useful as uricosuric agents
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CA2813555C (en) * 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
WO2012056442A1 (en) * 2010-10-28 2012-05-03 Mapi Pharma Holdings (Cyprus) Limited Polymorphs of febuxostat
PL2658846T3 (pl) 2010-12-30 2017-05-31 Ardea Biosciences, Inc. Polimorficzne postaci kwasu 2-(5-bromo-4-(4-cyklopropylo-naftalen-1-ylo)-4h-1,2,4-triazol-3-ilotio)octowego i jego zastosowania
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014010495A2 (pt) * 2011-11-03 2017-04-25 Ardea Biosciences Inc composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
PT2998296T (pt) 2013-05-13 2018-06-15 Shanghai hengrui pharmaceutical co ltd Derivado de ácido cicloalquilo, método de preparação do mesmo e suas aplicações fabmacêuticas
CN104447589B (zh) * 2013-11-20 2017-01-11 广东东阳光药业有限公司 一种尿酸调节剂的制备方法及其中间体
US10351536B2 (en) * 2013-11-22 2019-07-16 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
WO2015095703A1 (en) * 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
CN105294585B (zh) * 2014-07-02 2019-02-12 成都海创药业有限公司 一种治疗痛风的化合物
CN104341364A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑丙二酸类化合物、其制备方法及用途
CN104341365A (zh) * 2014-10-27 2015-02-11 张远强 卤代三氮唑丙二酸类化合物、其制备方法及用途
CN104326995A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326996A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途
CN104326994A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104529848A (zh) * 2014-11-10 2015-04-22 安徽万邦医药科技有限公司 一种1-环丙基-4-异硫氰酰基萘的合成方法
EP3915542B1 (en) 2014-12-23 2023-11-22 Dyve Biosciences, Inc. Formulations for transdermal administration
CN104710374A (zh) * 2015-04-14 2015-06-17 安徽省逸欣铭医药科技有限公司 一种痛风新化合物及制备方法、用途及其药物制剂
CN106187926B (zh) * 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105301126B (zh) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 一种托匹司他有关物质的分析方法
WO2017091513A1 (en) * 2015-11-24 2017-06-01 Daiichi Sankyo Company, Limited Novel azole derivatives as apelin receptor agonist
WO2017114352A1 (en) 2015-12-28 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Indolizine derivatives, composition and methods of use
US20170319552A1 (en) * 2016-02-24 2017-11-09 Ardea Biosciences, Inc. Atropisomers of triazole derivative
CN107176930B (zh) * 2016-03-11 2020-12-01 广东赛烽医药科技有限公司 2-[5-溴-4-(4-氟代环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基]乙酸化合物及其应用
ES2961901T3 (es) 2016-05-23 2024-03-14 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Tiofeno, método de fabricación del mismo y aplicación farmacéutica del mismo
CN106074540B (zh) * 2016-06-10 2018-10-16 江西博屾医疗器械有限公司 一种用于高尿酸血症治疗的药物组合物及其应用
CN105943552A (zh) * 2016-06-17 2016-09-21 王枝宝 一种氢氧化钾的医药用途
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
CZ307277B6 (cs) * 2016-09-30 2018-05-09 Zentiva, K.S. Způsob výroby 2-(5-brom-4-(1-cyklopropylnaftalen-4-yl)-4H-1,2,4-triazol-3-ylthio)octové kyseliny - lesinuradu
US10513500B2 (en) 2016-11-10 2019-12-24 Apotex Inc. Crystalline forms of Lesinurad
EP3538151B1 (en) 2016-11-11 2024-06-26 Whitehead Institute for Biomedical Research Human plasma-like medium
US10351537B2 (en) 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
WO2019055880A2 (en) * 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. METHOD OF ADMINISTRATION AND TREATMENT
NZ765226A (en) 2017-11-23 2022-11-25 Medshine Discovery Inc Crystal form of urat1 inhibitor, and preparation method therefor
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
US12319712B2 (en) 2018-05-09 2025-06-03 Vibrant Holdings, Llc Methods of synthesizing a polynucleotide array using photoactivated agents
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN109369783B (zh) * 2018-11-30 2021-09-10 昆明医科大学 一种多肽rdp1及其提纯方法与应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006101A (en) 1932-07-05 1935-06-25 Meaf Mach En Apparaten Fab Nv Reversing mechanism for dry gas meters
NL7112373A (enExample) * 1970-09-25 1972-03-28
US4198513A (en) * 1970-09-25 1980-04-15 Merck & Co., Inc. 1,2,4-Triazoles
JPS5641637B2 (enExample) 1973-11-26 1981-09-29
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US6832996B2 (en) 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
PT1129096E (pt) 1998-11-12 2003-09-30 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
US6414147B1 (en) 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
US6593077B2 (en) 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
CA2439820A1 (en) 2001-03-02 2002-09-12 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002349754B2 (en) 2002-01-28 2008-01-31 Fuji Yakuhin Co., Ltd. Novel 1,2,4-triazole compound
CA2484233A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
CA2496565C (en) * 2002-08-23 2013-04-02 Ribapharm Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
EA009734B1 (ru) 2003-09-25 2008-02-28 Янссен Фармацевтика Н.В. Производные пурина, ингибирующие репликацию вич
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2005046724A1 (ja) 2003-11-14 2005-05-26 Human Cell Systems, Inc. 血管障害や高血圧症の治療・予防剤、及びそのスクリーニング方法
CA2550091A1 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
CA2558224A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
CN1934095A (zh) * 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US20060013556A1 (en) * 2004-07-01 2006-01-19 Thomas Poslinski Commercial information and guide
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
KR101241716B1 (ko) 2004-08-25 2013-03-08 아디아 바이오사이언스즈 인크. ＨＩＶ 역 전사 효소의 억제제로서 Ｓ-트리아졸릴 α-메르캅토아세트아닐리드
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US7947707B2 (en) * 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
CA2653336C (en) 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP2120956A4 (en) 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
DK2217577T3 (da) 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2714669B1 (en) 2011-05-24 2017-04-26 Ardea Biosciences, Inc. Hypertension and hyperuricemia

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702986A (zh) * 2011-05-24 2014-04-02 阿迪亚生命科学公司 高血压和高尿酸血症
CN109045009A (zh) * 2011-11-04 2018-12-21 西玛贝医药公司 治疗痛风急性发作的方法
CN104066323A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 用于治疗患者亚群中痛风的方法
CN104066324A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 治疗痛风急性发作的方法
CN104066430A (zh) * 2012-01-27 2014-09-24 帝人制药株式会社 糖尿病的治疗药
CN104736522B (zh) * 2012-07-03 2018-10-09 阿迪亚生命科学公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的制备
CN104736522A (zh) * 2012-07-03 2015-06-24 阿迪亚生命科学公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的制备
CN107721931A (zh) * 2012-11-14 2018-02-23 帝人制药株式会社 吡啶衍生物
CN104797570B (zh) * 2012-11-14 2017-11-07 帝人制药株式会社 吡啶衍生物
CN104797570A (zh) * 2012-11-14 2015-07-22 帝人制药株式会社 吡啶衍生物
CN102973530A (zh) * 2012-12-14 2013-03-20 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
CN105263913A (zh) * 2013-06-14 2016-01-20 广东东阳光药业有限公司 硫代1,2,4-三唑衍生物及其制备方法
WO2015054960A1 (zh) * 2013-10-15 2015-04-23 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN103524440A (zh) * 2013-10-15 2014-01-22 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN104447590B (zh) * 2013-11-22 2017-11-28 苏州晶云药物科技有限公司 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1，2，4‑三唑‑3‑基硫基)乙酸的晶型及其制备方法
CN104447590A (zh) * 2013-11-22 2015-03-25 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的晶型及其制备方法
CN106883190A (zh) * 2013-12-02 2017-06-23 苏州晶云药物科技有限公司 雷西纳得的钠盐的晶型及其制备方法
CN104387333B (zh) * 2013-12-02 2018-04-17 苏州晶云药物科技有限公司 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1，2，4‑三唑‑3‑基硫基)乙酸钠的晶型及其制备方法
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN104387333A (zh) * 2013-12-02 2015-03-04 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的晶型及其制备方法
CN106866559A (zh) * 2013-12-20 2017-06-20 苏州晶云药物科技有限公司 雷西纳得的共晶及其制备方法
CN104529919A (zh) * 2013-12-20 2015-04-22 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的共晶及其制备方法
CN106866559B (zh) * 2013-12-20 2019-05-17 苏州晶云药物科技股份有限公司 雷西纳得的共晶及其制备方法
CN104529919B (zh) * 2013-12-20 2018-04-06 苏州晶云药物科技有限公司 2‑(5‑溴‑4‑(4‑环丙基萘‑1‑基)‑4h‑1，2，4‑三唑‑3‑基硫基)乙酸的共晶及其制备方法
CN104478815A (zh) * 2013-12-23 2015-04-01 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的多种盐、它们的晶型及其制备方法
CN104068288A (zh) * 2014-07-25 2014-10-01 许伟琦 一种防尿路结石的饲料添加剂
CN104326993A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370841A (zh) * 2014-10-27 2015-02-25 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341363A (zh) * 2014-10-27 2015-02-11 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341362A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370842A (zh) * 2014-10-27 2015-02-25 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104327000A (zh) * 2014-10-27 2015-02-04 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326998A (zh) * 2014-10-27 2015-02-04 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN107108478A (zh) * 2014-12-29 2017-08-29 日本化学药品株式会社 Urat1抑制剂
CN105985295A (zh) * 2015-02-17 2016-10-05 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
CN105985295B (zh) * 2015-02-17 2018-11-20 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
CN109053608A (zh) * 2015-02-17 2018-12-21 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物、其药物组合物和用途
WO2016155653A1 (zh) * 2015-04-03 2016-10-06 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
US10183915B2 (en) 2015-04-03 2019-01-22 Medshine Discovery Inc. Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof
CN107921054A (zh) * 2015-08-26 2018-04-17 斯塔根有限公司 细胞内atp增强剂
CN107921054B (zh) * 2015-08-26 2020-12-04 斯塔根有限公司 细胞内atp增强剂
CN107337649A (zh) * 2016-04-29 2017-11-10 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
US10633351B2 (en) 2016-06-17 2020-04-28 Medshine Discovery Inc. Halogenated compound and axially chiral isomer thereof
CN109476611A (zh) * 2016-06-17 2019-03-15 南京明德新药研发股份有限公司 一种卤代化合物及其轴手性异构体
CN109476611B (zh) * 2016-06-17 2022-08-23 南京明德新药研发有限公司 一种卤代化合物及其轴手性异构体
WO2017215589A1 (zh) * 2016-06-17 2017-12-21 南京明德新药研发股份有限公司 一种卤代化合物及其轴手性异构体
WO2018023851A1 (zh) * 2016-08-03 2018-02-08 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
AU2016417542B2 (en) * 2016-08-03 2020-01-30 Shandong University Imidazopyridine thioglycolic acid derivative, preparation method therefor and application thereof
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
CN108164471B (zh) * 2016-12-07 2019-09-13 浙江京新药业股份有限公司 Lesinurad衍生物及其制备方法和用途
CN108164471A (zh) * 2016-12-07 2018-06-15 浙江京新药业股份有限公司 Lesinurad衍生物及其制备方法和用途
CN108947919B (zh) * 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2018210354A1 (zh) * 2017-05-17 2018-11-22 浙江华海药业股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
CN108947919A (zh) * 2017-05-17 2018-12-07 上海奥博生物医药技术有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
CN111527073A (zh) * 2017-12-15 2020-08-11 南京明德新药研发有限公司 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
CN111527073B (zh) * 2017-12-15 2022-03-15 南京明德新药研发有限公司 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
US11352331B2 (en) 2017-12-15 2022-06-07 Medshine Discovery Crystal and salt of 4-(naphthalen-1-yl)-4H-1,2,4-triazole compound and preparation method therefor
WO2019114838A1 (zh) * 2017-12-15 2019-06-20 南京明德新药研发股份有限公司 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
CN111320588A (zh) * 2018-12-14 2020-06-23 上海奥博生物医药技术有限公司 一种纯化Lesinurad杂质的方法
CN111320588B (zh) * 2018-12-14 2024-02-09 上海奥博生物医药股份有限公司 一种纯化Lesinurad的方法

Also Published As

Publication number Publication date
HK1172326A1 (en) 2013-04-19
PL2217577T3 (pl) 2015-01-30
NZ601774A (en) 2013-07-26
AU2012203172B2 (en) 2013-10-10
JP2012184234A (ja) 2012-09-27
CL2008003529A1 (es) 2009-11-27
PT2217577E (pt) 2014-10-20
US20170281601A1 (en) 2017-10-05
ZA201003769B (en) 2011-02-23
AU2008329673A1 (en) 2009-06-04
HUS1900009I1 (hu) 2019-03-28
CA2706858C (en) 2013-12-24
AR069753A1 (es) 2010-02-17
CN102643241B (zh) 2015-01-21
JP5905934B2 (ja) 2016-04-20
LUC00103I2 (enExample) 2019-12-27
US20110293719A1 (en) 2011-12-01
WO2009070740A3 (en) 2009-08-13
US20120164222A1 (en) 2012-06-28
US20160221970A1 (en) 2016-08-04
JP5099794B2 (ja) 2012-12-19
TN2010000237A1 (en) 2011-11-11
US20110268801A1 (en) 2011-11-03
KR101291643B1 (ko) 2013-08-01
US20190142805A1 (en) 2019-05-16
US10183012B2 (en) 2019-01-22
EP2842948A1 (en) 2015-03-04
NZ585583A (en) 2011-09-30
ME01996B (me) 2015-05-20
LTPA2019003I1 (lt) 2019-02-25
CN103058944B (zh) 2015-08-05
NO2016016I1 (no) 2016-08-17
US20090197825A1 (en) 2009-08-06
US8546437B2 (en) 2013-10-01
TWI415840B (zh) 2013-11-21
CY2019010I2 (el) 2019-11-27
EA201000897A1 (ru) 2010-12-30
DK2217577T3 (da) 2014-10-20
EP2217577A4 (en) 2010-12-08
KR101411806B1 (ko) 2014-06-24
LUC00103I1 (enExample) 2019-02-19
US20140005136A1 (en) 2014-01-02
AU2012203172A1 (en) 2012-06-21
EP2217577B1 (en) 2014-08-06
RS53569B1 (sr) 2015-02-27
ME01294B (me) 2013-06-20
BRPI0819847A2 (pt) 2020-10-06
HK1180337A1 (en) 2013-10-18
BRPI0819847B1 (pt) 2022-01-11
MY147370A (en) 2012-11-30
NO2016016I2 (no) 2016-08-17
IL205974A0 (en) 2010-11-30
US8283369B2 (en) 2012-10-09
CY2019010I1 (el) 2019-11-27
HRP20140950T1 (hr) 2014-12-05
AU2008329673C1 (en) 2012-10-25
EA018193B1 (ru) 2013-06-28
MA31936B1 (fr) 2010-12-01
US8084483B2 (en) 2011-12-27
AU2008329673B2 (en) 2012-04-12
IL205974A (en) 2015-03-31
EP2217577A2 (en) 2010-08-18
SG183721A1 (en) 2012-09-27
JP2011504935A (ja) 2011-02-17
NZ595035A (en) 2012-11-30
CN102643241A (zh) 2012-08-22
ECSP10010310A (es) 2010-07-30
CA2706858A1 (en) 2009-06-04
MX2010005776A (es) 2010-08-31
EA201270666A1 (ru) 2012-12-28
KR20120084787A (ko) 2012-07-30
ES2513390T3 (es) 2014-10-27
JP2014196373A (ja) 2014-10-16
US8357713B2 (en) 2013-01-22
SI2217577T1 (sl) 2014-11-28
CN103058944A (zh) 2013-04-24
NZ601786A (en) 2014-02-28
EA018193B3 (ru) 2014-07-30
TW200927733A (en) 2009-07-01
WO2009070740A2 (en) 2009-06-04
KR20100085195A (ko) 2010-07-28

Similar Documents

Publication Publication Date Title
CN103058944B (zh) 调节血液尿酸水平的化合物
CN102186832B (zh) 调节尿酸含量的化合物、组合物及其使用方法
HK1146939A (en) Novel compounds and compositions and methods of use
HK1180337B (en) Compounds useful in the modulation of blood uric acid levels
HK1172326B (en) Compounds and compositions and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146939

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20101215

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1146939

Country of ref document: HK